Latest Regulatory Pathways News

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Island Pharmaceuticals has secured a critical collaboration with Texas Biomedical Research Institute to advance dose optimisation for its antiviral Galidesivir, targeting Marburg Virus Disease under the FDA Animal Rule. This second phase complements ongoing USAMRIID efforts and aims to de-risk pivotal study design with data from 32 non-human primates.

ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.

Island Pharmaceuticals is progressing its broad-spectrum antiviral Galidesivir amid a severe Ebola outbreak, securing government approvals in Uganda and outlining a dual clinical and regulatory development pathway targeting multiple deadly filoviruses.

Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.

Optiscan Imaging has begun commercial sales of its InSpecta™ microscopic imaging device in the US veterinary sector following FDA clearance, marking its first clinical device launch and a strategic expansion into a $15.87 billion market.

Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.

Prodigy Gold is progressing key regulatory approvals to restart mining at its Old Pirate gold mine, supported by encouraging ore sorting testwork that significantly upgrades gold grades and promises operational efficiencies.

Memphasys has locked in a three-year exclusive distribution agreement for its Felix™ sperm separation system in Thailand, targeting a key IVF market with 110 clinics and 20,000–30,000 cycles annually. The deal adds approximately A$430,500 in contracted revenue, lifting South-East Asian minimum contracts to about A$1 million and contributing to FY2026 Felix™ sales now exceeding A$3 million.

Native Mineral Resources (ASX:NMR) has cleared a key regulatory hurdle by submitting a Progressive Rehabilitation and Closure Plan for its Far Fanning Gold Project, while maintaining steady gold production at its Blackjack Gold Mine.

Akora Resources has completed a $3.3 million equity raise combining a $1.6 million placement and a modest $187,000 entitlement offer, positioning the company to push forward with mine development following its recent mining permit grant.

The Calmer Co. has won Coles' approval for its innovative Fiji Kava® FZZR™ product, extending its Australian supermarket reach while gearing up for a broader U.S. retail rollout supported by a key brokerage partnership.